Nutex Health price target raised to $45 from $30 at Benchmark

Benchmark raised the firm’s price target on Nutex Health to $45 from $30 and keeps a Buy rating on the shares. Nutex “checked all the boxes in 2Q with a big upside print,” positive outlook with expanding AEBITDA margins and strong growth in net operating cash flow, with the last being “most important,” the analyst tells investors.